IPSEN – Buy-back programme – Art 5 of MAR – Week 49- 2025
| Aggregated presentation by day and by market
Statement of transactions in own shares from December 1st to December 05th 2025 |
||||||
| Name of the issue | Identity code of the issuer (Legal Entity Identifier) |
Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 200 | 124,05000 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 831 | 123,81540 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 100 | 124,40000 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 01/12/2025 | FR0010259150 | 1897 | 124,16958 | XPAR |
| 3028 | 124,07209 | |||||
Attachment
Ipsen – January 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen nominates Peter Guenter to its Board of Directors
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Ipsen – December 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – Half year statement – 2025 12 31
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
Ipsen – November 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
IPSEN – Buy-back programme – Art 5 of MAR – Week 48 – 2025
IPSEN – Buy-back programme – Art 5 of MAR – Week 47 – 2025